This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: Vivus

Golferdahl41 has a beef: "I read with interest your comments on Oculus Innovative Sciences (OCLS). My experience with the product Microcyn is 1. It cured a leg infection on a friend of mine that was not responding to antibiotics. 2. It cured the leg and foot sores from diabetes on a lady who had amputation for the same problem on her other foot. 3. Cured the flesh-eating virus in the leg of another patient. I also checked with the company taking the veterinarian version to the public market and they say the reception and results are excellent. So, why do you continue to bash the company?"

I "bash" Oculus because because Microcyn's active ingredients are sodium hypochlorite (0.0036%) and hypochlorous acid (0.0025%), otherwise known as common household bleach and the chlorine used to keep swimming pools clean. That's it. Microcyn is a common disinfectant, widely available for pennies. Oculus has no data to support medical claims, no FDA drug approvals. Microcyn "cures" nothing.

Just because Oculus can put a common disinfectant in a spiffy bottle and sell it like a wonder drug doesn't make it one.

Craig L. asks, "Thanks for doing the Arena Pharmaceuticals (ARNA) lorcaserin live blog. It was helpful and interesting. I am curious to hear more from you on Orexigen Therapeutics (OREX - Get Report) if you have time to address it. It seems baffling to me, but you are more knowledgeable than I about these drugs. I just don't understand the move."

Craig refers to the sharply higher move in Orexigen immediately following the FDA advisory panel's negative vote on Arena's obesity drug lorcaserin. Orexigen roughly went from $5 to $7 but has now given up about half that gain.

Baffling is a good way to describe the reaction. With Arena and Vivus knocked down by FDA advisory panels, I assume traders viewed Orexigen as the last obesity drug play standing. Couple that with a paucity of shares to short and the stock moved higher.

From a fundamental perspective, I see Orexigen having a rough go at its own FDA advisory panel scheduled for Dec. 7. Orexigen has only one year of Contrave weight-loss data to present to the panel and the data are riddled with questions about cardiovascular and other side effects. After Arena and Vivus, we know the regulatory bar for obesity drugs is set high. You can't rule out an Orexigen victory on Dec. 7, but I'd be surprised if that happened.

And yes, absolutely, I will be live-blogging the Orexigen FDA panel on Dec. 7. I've done two of these obesity drug death matches so far, so it's time for the trifecta.
5 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
CTIC $1.22 -1.20%
ALKS $72.22 -1.60%
BCRX $10.52 -0.85%
CVM $0.46 -1.60%
OREX $2.33 -2.50%


Chart of I:DJI
DOW 17,842.66 +122.74 0.69%
S&P 500 2,093.40 +12.99 0.62%
NASDAQ 5,137.7370 +29.0710 0.57%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs